

Session Title: #90: Lymphoma and Plasma Cell Disorders

Session Type: General Poster Session

Session Date: Saturday, May 30

Location: Level 2, West Hall C

Session Start Time: 8:00 AM - 12:00 PM

Q7 #8544-Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): Final analysis of the HD12 trial of the German Hodgkin Study Group (GHSG).

Volker Diehl, MD

Q10 #8545-Randomized phase II trial on primary chemotherapy with high-dose methotrexate (HD-MTX) alone or associated with high-dose cytarabine (HD-araC) for patients with primary CNS lymphoma (I.E.L.S.G. #20 Trial): Tolerability, activity, and survival analyses.

Andres J Ferreri, MD

Q11 #8546-Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL).

Mariefrance Demierre, MD

Q12 #8547-Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood.

Matthew J Matasar, MD

Q13 #8548-Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma.

Nathan H Fowler, MD

Q14 #8549-Phase I/II study of concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Final results of JCOG0211.

Motoko Yamaguchi, MD, PhD

Q15 #8550-Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

Jeffrey Matous, MD

Q17 #8551-Retrospective analysis of CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL) treated with chemotherapy with or without rituximab.

Kana Miyazaki, MD, PhD

Q18 #8552-Long-term treatment of CTCL with the oral PNP inhibitor, forodesine.

Madeleine Duvic, MD

Q19 #8553-Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models.

Mengkun Zhang, MD

Q20 #8554-A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial.

Alain Delmer, MD

Q21 #8555-Application of the mantle international prognostic index (MIPI) to patients with mantle cell lymphoma treated with fludarabine/cyclophosphamide: Results from a UK NCRI Lymphoma Group study.

Simon Rule, MD

R1 #8556-Salvage chemotherapy with rituximab, oxaliplatin, cytosine arabinoside, and dexamethasone (ROAD) in patients with relapsed CD20+ aggressive B-cell lymphoma.

Patrick B Johnston, MD, PhD

R2 #8557-Observer variation in FDG PET-CT for staging of lymphoma.

Michael Hofman, MBBS, FRACP

R3 #8558-Autologous and allogeneic transplantation for aggressive T-cell lymphomas: A single institution experience.

Frederick Lansigan, MD

R4 #8559-A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma.

Byeong-Bae Park

R5 #8560-Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001.

Thomas E Witzig, MD

R6 #8561-PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

Owen O'Connor, MD, PhD

R7 #8562-Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome.

Jean-Francois Larouche, MD

R10 #8563-Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle-cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL).

Kevin Tay, MD

R11 #8564-Mature T-/NK-cell lymphomas: Prognostic factors and treatment outcome of patients treated on studies of the German High-Grade Lymphoma Study Group (DSHNHL).

Norbert Schmitz, MD

R12 #8565-Prediction of treatment response in subtypes of non-Hodgkin's lymphoma by in vivo 31P MR spectroscopy before treatment.

Fernando Arias-Mendoza, MD, PhD

R13 #8566-A phase I trial evaluating the safety and biological activity of iboctadekin (rhIL-18) in combination with rituximab in patients with CD20+ B-cell non-Hodgkin's lymphoma.

Michael J Robertson, MD

R14 #8567-Effects of *FCGR3A* and *FCGR2A* polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab.

Julie Vose, MD

R15 #8568-Complete response (CR) to ifosfamide, gemcitabine, and vinorelbine (IGE) and outcome in relapsed/refractory Hodgkin's lymphoma (HL) patients.

Antonella Anastasia, MD

R17 #8569-Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003).

Craig B Reeder, MD

R18 #8570-The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.

Changhoon Yoo, MD

R19 #8571-Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma.

Peter R Baum, PhD

R20 #8572-Vorinostat in combination with bexarotene in advanced cutaneous T-cell lymphoma: A phase I study.

Reinhard Dummer

R21 #8573-Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus (EBV) antigens in patients with EBV-negative Hodgkin's disease.

Holbrook E Kohrt, MD

S1 #8574-ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Wyndham Wilson, MD, PhD

S2 #8575-Analysis of prognostic factors in patients with adult T-cell leukemia/lymphoma.

Brady E Beltran, MD

S3 #8576-Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.

Ikir Maraj, MD

S4 #8577-Bortezomib plus modified R-CHOP as initial therapy for indolent B-cell lymphomas: Phase I results.

Christopher Flowers, MD, MS

S6 #8579-Rituximab plus gemcitabine, ifosfamide, oxaliplatin (R-GIFOX) as salvage therapy for recurrent Hodgkin lymphoma.

Gaetano Corazzelli

S7 #8580-Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma.

Jasmine M Zain, MD

S10 #8581-Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP).

Dita Gratzinger, MD, PhD

S11 #8582-An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL).

Edwin Kingsley, MD

S12 #8583-Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma.

Patil Ritesh, MD

S13 #8584-Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL).

Luca Paoluzzi, MD

S15 #8586-Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study.

David S Siegel, MD, PhD

S17 #8587-Prognostic value of stringent complete response (sCR) post-autologous stem cell transplant (SCT) in multiple myeloma (MM).

Prashant Kapoor, MD

S19 #8589-Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total therapies 2 and 3.

Bijay Nair, MD

S20 #8590-Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP).

Sarah Waheed, MD

S21 #8591-Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM).

Jatin J Shah, MD

T1 #8592-EPOCH-F: A salvage regimen for multiple myeloma prior to reduced intensity allogeneic hematopoietic stem cell transplantation.

Saad Jamshed, MD

T2 #8593-Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma.

Jonathan L Kaufman

T3 #8594-Comparison of lenalidomide plus dexamethasone therapy used at first relapse versus later salvage therapy in relapsed or refractory multiple myeloma patients.

Edward A Stadtmauer, MD

T4 #8595-MDS-associated cytogenetic abnormalities (MDS-CA) after total therapy (TT) regimens for newly diagnosed multiple myeloma (MM): Apparent surge after introduction of post-transplant consolidation chemotherapy (CONS) in TT2 and TT3.

Klaus Hollmig, MD

T5 #8596-Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients.

Nina Shah, MD

T6 #8597-A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.

Sagar Lonial, MD

T8 #8599-Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival.

John Crowley, PhD

T9 #8600-Prognostic impact of bone marrow CD138 immunohistochemistry (IHC) prior to autologous stem cell transplant (ASCT) for multiple myeloma (MM).

Matthew C Foster, MD

T10 #8601-Effect of the specific P53 stabilizer CBS9106 on multiple myeloma (MM).

Hiroshi Ikeda, MD, PhD

T12 #8603-Impact of dexamethasone responsiveness on long-term outcome in patients with newly diagnosed myeloma.

Shirshendu Sinha, MBBS

T14 #8605-Plasma cell leukemia: A SEER database analysis.

Giridharan Ramsingh, MD, MBBS

Session Title: #221: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall D2

Session Start Time: 9:30 AM - 12:00 PM

Importance of Genetic Heterogeneity in Curing Adult Acute Leukemia (AL)

Clara D. Bloomfield, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Allen S. Lichter, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Richard L. Schilsky, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Joseph S. Bailes, MD

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Nancy E. Davidson, MD

Session Title: #22: Lymphoma

Session Type: Oral Presentation

Session Date: Saturday, May 30

Location: Level 2, West Hall F1

Session Start Time: 1:00 PM - 3:45 PM

Lymphoma

Nancy Bartlett, MD

Lymphoma

Kenneth Stuart Cohen, MD

#8506-A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin's lymphoma.

David Cunningham, MD

#8507-Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003-3).

Nicolas Mounier

#8508-Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

Ivana N Micallef, MD

Discussion: Beyond R-CHOP-21 in Large Cell Lymphoma

John P. Leonard, MD

#8509-R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

Christian Gisselbrecht, MD

#8510-Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors.

Andrew M Evens, DO

#8511-Utilization of radiation therapy in early-stage Hodgkin disease and its impact on survival.

Justin Rineer, MD

Discussion: Is there a Role for Radiotherapy in Early Stage Hodgkin's Lymphoma

Nancy Bartlett, MD

#8512-Long-term follow-up of patients with follicular lymphoma (FL) receiving single agent rituximab at two different schedules in study SAKK 35/98.

Michele E Ghielmini, MD

#8513-Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Morie A. Gertz, MD

Discussion: Durability of Rituximab Responses in Indolent Lymphoma

Ian W Flinn, MD, PhD

Session Title: #114: Challenging Lymphomas in Pediatrics

Session Type: Education Session

Session Date: Saturday, May 30

Location: Level 3, W304E

Session Start Time: 1:15 PM - 2:30 PM

The Pathologist's Perspective: Update on the Pathobiology of Uncommon Childhood Lymphomas

Mihaela M. Onciu, MD

Clinical Features and Treatment Approaches for the Uncommon Non-Hodgkin Lymphoma Subtypes of Childhood

John Torsten Sandlund, MD

Novel Treatment Approaches for Refractory CNS Lymphoma: Lessons Learned from the Adult Experience

Lauren E. Abrey, MD

Session Title: #215: Forum on Reimbursement

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall E1

Session Start Time: 3:00 PM - 4:15 PM

Forum on Reimbursement

Joseph S. Bailes, MD

Forum on Reimbursement

Terry S. Coleman, JD

Session Title: #227: Pediatric Oncology Award and Lecture

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 3, W304E

Session Start Time: 3:00 PM - 4:15 PM

Pediatric Oncology Award and Lecture

William E. Evans, PharmD

Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia (ALL)

Mary V. Relling, PharmD

Pediatric Oncology Award and Lecture

Nancy E. Davidson, MD

Session Title: #122: Advances in T-Cell Lymphoma Biology, Diagnosis, and Treatment

Session Type: Education Session

Session Date: Saturday, May 30

Location: Level 2, West Hall F1

Session Start Time: 4:45 PM - 6:00 PM

The Aggressive T-cell Lymphomas- Diagnosis and Prognostic Factors

Julie Vose, MD

Treatment Strategies for T-cell Lymphomas- Initial Therapy and Stem Cell Transplantation

Francine M. Foss, MD

Novel Therapies for Aggressive T-cell Lymphomas

Barbara Pro, MD

Session Title: #216: Global Perspective on Prevention and Intervention in Female Malignancies

Session Type: Special Session

Session Date: Saturday, May 30

Location: Level 2, West Hall E1

Session Start Time: 4:45 PM - 6:00 PM

Breast Health Global Initiative

Benjamin O. Anderson, MD

Global Perspective on BRCA Mutation

Allison W. Kurian, MD, MSc

Female Non-smoking Adenocarcinoma of Lung: Confronting a Unique Disease Entity

Tony Mok, MD

What it Takes to Eradicate Cancer of the Cervix: HPV Vaccine

Richard B.S. Roden, PhD

What it Takes to Eradicate Cancer of Cervix: Screening

Carlos Santos, MD

Session Title: #16: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Oral Presentation

Session Date: Sunday, May 31

Location: Level 2, West Hall D2

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day I including Clinical Trials Participation Awards

Daniel F. Hayes, MD

Clinical Trials Participation Awards

Richard L. Schilsky, MD

Breast Cancer □ Local-Regional and Adjuvant Therapy

Lori J. Pierce, MD

Lymphoma

Jonathan W. Friedberg, MD

Melanoma

David F. McDermott, MD

Patient and Survivor Care

Teresa Gilewski, MD

Gastrointestinal (Colorectal) Cancer

John Marshall, MD

Session Title: #234: Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Session Type: Clinical Problems In Oncology

Session Date: Sunday, May 31

Location: Level 2, W205A

Session Start Time: 8:00 AM - 9:15 AM

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Todd M. Zimmerman, MD

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Raymond Comenzo, MD

Management of Unusual Plasma Cell Dyscrasias (Excluding Myeloma)

Angela Dispenzieri, MD

Session Title: #24: Myeloma

Session Type: Oral Presentation

Session Date: Sunday, May 31

Location: Level 2, West Hall F1

Session Start Time: 9:00 AM - 11:45 AM

Myeloma

Robert Z. Orlowski, MD, PhD

Myeloma

Ravi Vij, MD

#8515-A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients.

Antonio P Palumbo, MD

#8516-Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial.

Stefan Knop

#8517-Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial.

Andrzej J Jakubowiak, MD, PhD

#8518-Phase II study of pegylated liposomal doxorubicin (PLD), low-dose dexamethasone (DEX), and lenalidomide (LEN) in patients with newly diagnosed (ND) multiple myeloma (MM).

Rachid Baz, MD

Discussion: Update on Induction Regimens for Multiple Myeloma

S. Vincent Rajkumar, MD

#8519-Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ark) Total Therapy (TT) trials.

Bart Barlogie, MD, PhD

#8520-Bone marrow microenvironment (ME) associated genes identified prior to all altered 48 hours after bortezomib test-dose application and prognosis of multiple myeloma (MM) treated with total therapy 3 (TT3).

Pingping Qu, PhD

#8521-The multi-institutional myeloma group clinico-genomic risk stratification system: A blinded validation.

Sascha A Tuchman, MD

Discussion: New Prognostic Tools in Myeloma

Rafael Fonseca, MD

#8522-Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma.

Madhav V Dhodapkar, MD

Discussion: Immunobiology of Myeloma

Ivan Borrello, MD

Session Title: #285: ASCO/AACR Joint Session: Personalized Cancer Therapy - Pathways to Progress

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 2, West Hall D1

Session Start Time: 9:30 AM - 10:45 AM

Welcome and Introduction

Raymond DuBois, MD, PhD

Welcome and Introduction

Richard L. Schilsky, MD

Insulin and IGF-I as therapeutic targets and modifiable metabolic predictors of prognosis

Michael N. Pollak, MD

Sonic Hedgehog Pathway

Daniel D. Von Hoff, MD

Personalizing Cancer Therapy - The PI3K/AKT Pathway

Garth Powis, D.Phil

Session Title: #220: Training Program Directors' Special Session: How to Be a Program Director

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 3, Lecture Hall W300

Session Start Time: 10:30 AM - 12:30 PM

Training Program Directors' Special Session: How to Be a Program Director

Timothy Jerome Moynihan, MD

Training Program Directors' Special Session: How to Be a Program Director

Linda J. Burns, MD

Training Program Directors' Special Session: How to Be a Program Director

Michael P. Kosty, MD, FACP

Session Title: #1: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Presentation

Session Date: Sunday, May 31

Location: Level 2, West Hall D2

Session Start Time: 1:00 PM - 4:00 PM

Plenary Session including Science of Oncology Award and Lecture

Richard L. Schilsky, MD

Plenary Session including Science of Oncology Award and Lecture

Everett E. Vokes, MD

Plenary Session including Science of Oncology Award and Lecture

Nancy E. Davidson, MD

Cancer Genomes and their Implications for Understanding and Managing Cancer

Bert Vogelstein, MD

#1-A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials).

Gordon J Rustin, MD

Discussion

Beth Karlan, MD

#2-Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results.

Stephen J Schuster, MD

Discussion

Ronald Levy, MD

Discussion

Merrill J. Egorin, MD

#3-Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O'Shaughnessy, MD

#LBA4-A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

Norman Wolmark, MD

Discussion

To Be Determined

Session Title: #123: Cancer Vaccines: Where Do We Go from Here?

Session Type: Education Session

Session Date: Sunday, May 31

Location: Level 2, West Hall F1

Session Start Time: 4:45 PM - 6:00 PM

cancer vaccine strategies for hematologic malignancies

Larry W. Kwak, MD, PhD

cancer vaccine development for solid malignancies

Glenn Dranoff, MD

overcoming immune suppression

Carl H. June, MD

Session Title: #223: B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Session Type: Special Session

Session Date: Sunday, May 31

Location: Level 3, W330A

Session Start Time: 4:45 PM - 6:00 PM

Geriatric Oncology and the Ultimate Personalized Cancer Care

Martine Extermann, MD

B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Nancy E. Davidson, MD

Session Title: #17: Highlights of the Day II including Partners in Progress Award

Session Type: Oral Presentation

Session Date: Monday, June 1

Location: Level 2, West Hall D2

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day II including Partners in Progress Award

Nancy E. Davidson, MD

Highlights of the Day II including Partners in Progress Award

Everett E. Vokes, MD

Partners in Progress Award

Diane Blum, MSW

Genitourinary (Prostate) Cancer

Nancy Ann Dawson, MD

Gynecologic Cancer

Robert L Coleman, MD

Myeloma

Kenneth C Anderson, MD

Head and Neck Cancer

Marshall R. Posner, MD

Lung Cancer - Metastatic

Bruce E. Johnson, MD

Session Title: #173: Therapeutic Options for Multiple Myeloma: Transplant versus Nontransplant

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 2, West Hall F3

Session Start Time: 8:00 AM - 9:15 AM

Non-transplant regimens for treatment of myeloma

Donna Ellen Reece, MD

Autologous and Allogeneic Transplant Management for Multiple Myeloma

Jean L. Harousseau, MD

Personalized care plan for treatment of myeloma

Morie A. Gertz, MD

Session Title: #284: ASCO/American Society of Hematology Symposium: The Best of ASH

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 2, West Hall F5

Session Start Time: 8:00 AM - 9:15 AM

ASCO/American Society of Hematology Symposium: The Best of ASH

Linda J. Burns, MD

ASCO/American Society of Hematology Symposium: The Best of ASH

Richard L. Schilsky, MD

TET2 Is a Novel Tumor Suppressor Gene Inactivated in Myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F Event

Francois Delhommeau, PharmD, PhD

A Prospective Randomized Study Comparing Rituximab and Dexamethasone vs Dexamethasone Alone in ITP: Results of Final Analysis and Long-Term Follow Up

Francesco Zaja, MD

Non-Myeloablative Hematopoietic Stem Cell Transplantation in Older Patients with AML and MDS: Results from the Center for International Blood and Marrow Transplant Research (CIBMT)

Brian L. McClune, MD

A Randomized Double-Blind Placebo-Controlled Study on Nadroparin for Prophylaxis of Thromboembolic Events in Cancer Patients Receiving Chemotherapy: The PROTECHT Study

Giancarlo Agnelli, MD

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Julia Bohlius, MD, MScPH

Session Title: #222: American Cancer Society Award and Lecture

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 3, W304A

Session Start Time: 9:45 AM - 11:00 AM

A Family Based Approach to Primary Prevention of Breast Cancer

Olufunmilayo I. Olopade, MBBS, FACP

American Cancer Society Award and Lecture

Nancy E. Davidson, MD

Session Title: #246: New Agents for Lymphoma

Session Type: Clinical Science Symposium

Session Date: Monday, June 1

Location: Level 2, West Hall F3

Session Start Time: 11:30 AM - 1:00 PM

New Agents for Lymphoma

Richard F. Ambinder, MD, PhD

#8500-Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL).

Nancy Bartlett, MD

Discussion: Immunoconjugates and novel approaches in Hodgkins Lymphoma

Richard F. Ambinder, MD, PhD

#8501-Novel organic arsenic molecule darinaparsin: Development of IV and oral forms.

Izidore Lossos, MD

Discussion: Mechanisms of Action of Arsenicals in Hematologic Malignancies

Meir Wetzler, MD

#8502-Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL).

Bruce D Cheson, MD

Discussion: Targeting Survival Pathways and Challenges in Drug Development in Aggressive Lymphoma

Anas Younes, MD

Session Title: #376: ASCO/Radiological Society of North America Joint Session - Optimize Your Patient's Care: Talk to Your Radiologist

Session Type: Education Session

Session Date: Monday, June 1

Location: Level 4, Valencia Room, W415D

Session Start Time: 11:30 AM - 12:45 PM

Digesting the Alphabet Soup of Neuroradiology: What does it mean to you and your patient?

Srinivasan Mukundan, Jr., MD, PhD

Imaging of abdominopelvic malignancies: What to tell your Radiologist

Fergus V. Coakley, MD

Interventional Radiology: Ablation, Embolization, Tissue Acquisition, Kyphoplasty, and Other Image-Guided Techniques for the Cancer Patient

Stephen B. Solomon, MD

Fostering Communication between Radiologists and Oncologists: Be Bold, Break the Mold

Annick D. Van den Abbeele, MD

ASCO/Radiological Society of North America Joint Session - Optimize Your Patient's Care: Talk to Your Radiologist

Patrick J. Loehrer, MD

Session Title: #63: Lymphoma and Plasma Cell Disorders

Session Type: Poster Discussion

Session Date: Monday, June 1

Location: Level 2, W240A

Session Start Time: 2:00 PM - 6:00 PM

1 #8523-Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma.

Ruth Pettengell, MD

2 #8524-Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases.

Gregory S Dueck, MD, MSc

3 #8525-Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).

Jia Ruan, MD, PhD

4 #8526-Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.

David J Andorsky, MD

5 #8527-A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).

Peter M Voorhees, MD

6 #8528-Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma.

Peter Kamper, MD

7 #8529-In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.

John Timmerman, MD

8 #8530-Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies.

Steven L Allen

9 #8531-Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.

Kristie A Blum, MD

10 #8532-Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3).

Twyla B Bartel, DO

11 #8533-FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone.

Neeta Pandit-Taskar, MD

12 #8534-First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03.

Christian J Taverna, MD

13 #8535-Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.

Irene M Ghobrial, MD

14 #8536-Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

Kenneth C Anderson, MD

15 #8537-PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.

Ravi Vij, MD

16 #8538-Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).

John D Shaughnessy, PhD

17 #8539-Clinical and biological significance of microRNA profiling in patients with myeloma.

Sophia Adamia, PhD

18 #8540-Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL).

Heather J Landau, MD

19 #8541-PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results.

Ruben Niesvizky, MD

20 #8542-Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).

Andrew Spencer

21 #8543-Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL).

Francisco J Hernandez-Ilizaliturri, MD

Session Title: #218: ASCO/ESMO Symposium: Global Clinical Trials - Challenges and Solutions

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 2, West Hall F5

Session Start Time: 3:00 PM - 4:15 PM

Welcome and Introduction

Jose Baselga, MD

Accrual Challenges and Proposed Solutions in the U.S. and Europe

George W. Sledge, MD

Optimizing Biospecimen Acquisition Across Borders

Fatima Cardoso, MD

Improving International Collaboration and Trial Design in a Flat World

Richard D. Gelber, PhD

Summary and Conclusions: Focus on Solutions

Richard L. Schilsky, MD

Session Title: #247: New Agents for Multiple Myeloma

Session Type: Clinical Science Symposium

Session Date: Monday, June 1

Location: Level 2, West Hall F1

Session Start Time: 3:00 PM - 4:30 PM

New Agents for Multiple Myeloma

Carol Ann Huff, MD

Discussion: Current Use of Proteasome Inhibitors in Myeloma

Carol Ann Huff, MD

#8503-Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study.

Paul Gerard Guy Richardson, MD

Discussion: Rational Combinations of Proteasome Inhibitors with Novel Therapeutics

Kapil N. Bhalla, MD

#8504-Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM).

Sundar Jagannath, MD

#8505-Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM).

Craig C Hofmeister, MD

Discussion: Next Generation Proteasome Inhibitors

Michael Wang, MD

Session Title: #217: Molecular Imaging and Cancer Therapy: Focus on Clinical Trials: An ASCO/SNM Joint Education Session

Session Type: Special Session

Session Date: Monday, June 1

Location: Level 4, Valencia Room, W415D

Session Start Time: 4:45 PM - 6:00 PM

Welcome

Robert W. Atcher, PhD, MBA

Welcome

Richard L. Schilsky, MD

Overview of Molecular Imaging Applications to Cancer Clinical Trials

David A. Mankoff, MD, PhD

Imaging the Pharmacodynamics of Cancer Therapy Using Molecular Imaging

Eric Aboagye, PhD

Proliferation Imaging to Measure Therapy Response

Anthony Frank Shields, MD, PhD

Imaging as a Cancer Biomarker - Lessons Learned from Tissue Biomarkers

Daniel F. Hayes, MD

Session Title: #64: Lymphoma and Plasma Cell Disorders

Session Type: Poster Discussion

Session Date: Monday, June 1

Location: Level 2, West Hall F1

Session Start Time: 5:00 PM - 6:00 PM

Lymphoma and Plasma Cell Disorders

Ian W Flinn, MD, PhD

1 #8523-Randomized phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma.

Ruth Pettengell, MD

2 #8524-Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases.

Gregory S Dueck, MD, MSc

3 #8525-Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma (MCL).

Jia Ruan, MD, PhD

Discussion: New Approaches in Aggressive Lymphoma

Sven De Vos, MD, PhD

4 #8526-Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.

David J Andorsky, MD

5 #8527-A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM).

Peter M Voorhees, MD

6 #8528-Tumor-infiltrating CD163-positive macrophages, clinicopathological parameters, and prognosis in classical Hodgkin lymphoma.

Peter Kamper, MD

7 #8529-In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.

John Timmerman, MD

Discussion: Targeting the Immune System in Lymphoma and Myeloma

Sattva Swarup Neelapu, MD

8 #8530-Subcutaneous injections of low doses of velvuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies.

9 #8531-Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy.

Kristie A Blum, MD

Discussion: Antibody Modifications for Enhanced Efficacy

Myron Stefan Czuczman, MD

10 #8532-Prognostic implications of comprehensive imaging with PET-CT, MRI, and X-rays and their biological and molecular correlates in multiple myeloma (MM) treated with total therapy 3 (TT3).

Twyla B Bartel, DO

11 #8533-FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone.

Neeta Pandit-Taskar, MD

Discussion: Role of PET Scanning in Myeloma

Ruben Niesvizky, MD

12 #8534-First results of long-term rituximab maintenance treatment in follicular lymphoma: Safety analysis of the randomized phase III trial SAKK 35/03.

Christian J Taverna, MD

13 #8535-Phase II trial of combination of bortezomib and rituximab in relapsed and/or refractory Waldenstrom macroglobulinemia.

Irene M Ghobrial, MD

14 #8536-Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

Kenneth C Anderson, MD

15 #8537-PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update.

Ravi Vij, MD

16 #8538-Use of bortezomib (BOR) pharmacogenomics (PG) to identify mechanisms of drug resistance and predict survival in multiple myeloma (MM) treated with total therapy 3 (TT3).

John D Shaughnessy, PhD

17 #8539-Clinical and biological significance of microRNA profiling in patients with myeloma.

Sophia Adamia, PhD

18 #8540-Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in patients with light-chain amyloidosis (AL).

Heather J Landau, MD

19 #8541-PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): Preliminary results.

Ruben Niesvizky, MD

20 #8542-Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM).

Andrew Spencer

21 #8543-Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL).

Francisco J Hernandez-Ilizaliturri, MD

Session Title: #18: Highlights of the Day III

Session Type: Oral Presentation

Session Date: Tuesday, June 2

Location: Level 2, West Hall D1

Session Start Time: 7:30 AM - 9:00 AM

Highlights of the Day III

Michael A. Carducci, MD

Genitourinary Cancer (Non-Prostate)

Primo Lara, MD

Leukemia, Myelodysplasia, and Transplantation

Charles Alan Schiffer, MD

Breast Cancer - Metastatic

Clifford Hudis, MD

Lung Cancer □ Local-Regional and Adjuvant Therapy

Antoinette J Wozniak, MD

Sarcoma

Suzanne George, MD

Gastrointestinal (Noncolorectal) Cancer

Andrew H. Ko, MD